Globeflex Capital L P Acquires 28,784 Shares of ANI Pharmaceuticals, Inc. $ANIP

Globeflex Capital L P boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 52.0% in the first quarter, Holdings Channel.com reports. The fund owned 84,145 shares of the specialty pharmaceutical company’s stock after acquiring an additional 28,784 shares during the quarter. ANI Pharmaceuticals comprises 1.0% of Globeflex Capital L P’s portfolio, making the stock its 26th biggest holding. Globeflex Capital L P’s holdings in ANI Pharmaceuticals were worth $6,471,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. Penn Capital Management Company LLC grew its holdings in shares of ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after purchasing an additional 131,030 shares during the last quarter. Artemis Investment Management LLP purchased a new position in ANI Pharmaceuticals in the 4th quarter worth about $1,706,000. Hussman Strategic Advisors Inc. purchased a new position in ANI Pharmaceuticals in the 4th quarter worth about $2,487,000. Finally, CenterBook Partners LP bought a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $1,518,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.9%

Shares of ANI Pharmaceuticals stock opened at $77.61 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 1 year low of $62.60 and a 1 year high of $99.50. The firm’s 50-day moving average is $81.28 and its two-hundred day moving average is $79.48. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 19.65 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same quarter last year, the firm posted $1.70 EPS. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

Insider Activity

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the sale, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. This trade represents a 20.65% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 85,179 shares of company stock valued at $6,722,596. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.